325 related articles for article (PubMed ID: 21844505)
1. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Chiocca EA; Aguilar LK; Bell SD; Kaur B; Hardcastle J; Cavaliere R; McGregor J; Lo S; Ray-Chaudhuri A; Chakravarti A; Grecula J; Newton H; Harris KS; Grossman RG; Trask TW; Baskin DS; Monterroso C; Manzanera AG; Aguilar-Cordova E; New PZ
J Clin Oncol; 2011 Sep; 29(27):3611-9. PubMed ID: 21844505
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma.
Kieran MW; Goumnerova L; Manley P; Chi SN; Marcus KJ; Manzanera AG; Polanco MLS; Guzik BW; Aguilar-Cordova E; Diaz-Montero CM; DiPatri AJ; Tomita T; Lulla R; Greenspan L; Aguilar LK; Goldman S
Neuro Oncol; 2019 Mar; 21(4):537-546. PubMed ID: 30883662
[TBL] [Abstract][Full Text] [Related]
3. Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.
Wheeler LA; Manzanera AG; Bell SD; Cavaliere R; McGregor JM; Grecula JC; Newton HB; Lo SS; Badie B; Portnow J; Teh BS; Trask TW; Baskin DS; New PZ; Aguilar LK; Aguilar-Cordova E; Chiocca EA
Neuro Oncol; 2016 Aug; 18(8):1137-45. PubMed ID: 26843484
[TBL] [Abstract][Full Text] [Related]
4. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.
Aguilar LK; Shirley LA; Chung VM; Marsh CL; Walker J; Coyle W; Marx H; Bekaii-Saab T; Lesinski GB; Swanson B; Sanchez D; Manzanera AG; Aguilar-Cordova E; Bloomston M
Cancer Immunol Immunother; 2015 Jun; 64(6):727-36. PubMed ID: 25795132
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir.
Smitt PS; Driesse M; Wolbers J; Kros M; Avezaat C
Mol Ther; 2003 Jun; 7(6):851-8. PubMed ID: 12788659
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model.
Tyynelä K; Sandmair AM; Turunen M; Vanninen R; Vainio P; Kauppinen R; Johansson R; Vapalahti M; Ylä-Herttuala S
Cancer Gene Ther; 2002 Nov; 9(11):917-24. PubMed ID: 12386830
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.
Ji N; Weng D; Liu C; Gu Z; Chen S; Guo Y; Fan Z; Wang X; Chen J; Zhao Y; Zhou J; Wang J; Ma D; Li N
Oncotarget; 2016 Jan; 7(4):4369-78. PubMed ID: 26716896
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.
Trask TW; Trask RP; Aguilar-Cordova E; Shine HD; Wyde PR; Goodman JC; Hamilton WJ; Rojas-Martinez A; Chen SH; Woo SL; Grossman RG
Mol Ther; 2000 Feb; 1(2):195-203. PubMed ID: 10933931
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.
Westphal M; Ylä-Herttuala S; Martin J; Warnke P; Menei P; Eckland D; Kinley J; Kay R; Ram Z;
Lancet Oncol; 2013 Aug; 14(9):823-33. PubMed ID: 23850491
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.
Germano IM; Fable J; Gultekin SH; Silvers A
J Neurooncol; 2003 Dec; 65(3):279-89. PubMed ID: 14682378
[TBL] [Abstract][Full Text] [Related]
11. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
13. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
14. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
16. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Nabors LB; Mikkelsen T; Hegi ME; Ye X; Batchelor T; Lesser G; Peereboom D; Rosenfeld MR; Olsen J; Brem S; Fisher JD; Grossman SA;
Cancer; 2012 Nov; 118(22):5601-7. PubMed ID: 22517399
[TBL] [Abstract][Full Text] [Related]
17. Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells.
Glaser T; Castro MG; Löwenstein PR; Weller M
Gene Ther; 2001 Mar; 8(6):469-76. PubMed ID: 11313826
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
Candolfi M; Yagiz K; Wibowo M; Ahlzadeh GE; Puntel M; Ghiasi H; Kamran N; Paran C; Lowenstein PR; Castro MG
Clin Cancer Res; 2014 Mar; 20(6):1555-1565. PubMed ID: 24501391
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Rainov NG; Fels C; Droege JW; Schäfer C; Kramm CM; Chou TC
Cancer Gene Ther; 2001 Sep; 8(9):662-8. PubMed ID: 11593335
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
